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Abstract
Background Idiopathic normal pressure hydrocephalus
(INPH) has no reliable biomarker to assist in the selection
of patients who could benefit from ventriculo-peritoneal
(VP) shunt insertion. The neurodegenerative markers T-
tau and Aβ1-42 have been found to successfully differen-
tiate between Alzheimer’s disease (AD) and INPH and
therefore are candidate biomarkers for prognosis and
shunt response in INPH. The aim of this study was to test
the predictive value of cerebrospinal fluid (CSF) T-tau
and Aβ1-42 for shunt responsiveness. In particular, we
pay attention to the subset of INPH patients with raised
T-tau, who are often expected to be poor surgical
candidates.
Methods Single-centre retrospective analysis of probable
INPH patients with CSF samples collected from 2006 to
2016. Index test: CSF levels of T-tau and Aβ1-42.
Reference standard: postoperative outcome. ROC analysis
assessed the predictive value.
Results A total of 144 CSF samples from INPH patients were
analysed. Lumbar T-tau was a good predictor of post-
operative mobility (AUROC 0.80). The majority of patients
with a co-existing neurodegenerative disease responded well,
including those with high T-tau levels.
Conclusion INPH patients tended to exhibit low levels of
CSF T-tau, and this can be a good predictor outcome.
However levels are highly variable between individuals.
Raised T-tau and being shunt-responsive are not mutually ex-
clusive, and such patients ought not necessarily be excluded
from having a VP shunt. A combined panel of markers may be
a more specific method for aiding selection of patients for VP
shunt insertion. This is the most comprehensive presentation
of CSF samples from INPH patients to date, thus providing
further reference values to the current literature.
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Introduction
Idiopathic normal-pressure hydrocephalus (INPH) is a condi-
tion that predominantly affects the elderly population, has a
prevalence of 0.02%–5.9% and affects an estimated 2 million
people within Europe [6, 10]. INPH presents with a triad of
cognitive deficits, impaired mobility and incontinence. The
mainstay of treatment is cerebrospinal fluid (CSF) diversion
via a ventriculo-peritoneal (VP) shunt [1, 3]. Selection of pa-
tients for VP shunt insertion remains a challenge since the
triad of symptoms in INPH is common in the elderly popula-
tion. The surgery for a VP shunt is not without risk and a
proportion of those with INPH do not benefit [16, 18].
Whilst prognostic tests are becoming more accurate, INPH
still has no reliable biomarker to assist in the selection of
patients for a VP shunt or for the monitoring of shunt function
[7, 9, 15, 16, 18].
Tau and Aβ1-42 are well defined as CSF biomarkers
that aid in the diagnosis of Alzheimer’s disease (AD) and
are potential prognostic markers in INPH [4, 8, 11–14].
Tau is a protein that promotes microtubule assembly and
stability and is found in neuronal axons [4]. Aβ1-42 is a
product of amyloid precursor protein (APP) that rapidly
aggregates to form the main component of diffuse plaques
[4]. The high CSF total-tau (T-tau) concentration is
thought to reflect neuroaxonal degeneration/injury and
low CSF Aβ1-42 correlates with senile plaque pathology
[4, 8].
T-tau and Aβ1-42 levels have been found to successfully
differentiate between AD and INPH [11, 12]. Patients with
INPH consistently appear to have low CSF levels of T-tau
and Aβ1-42 [8, 11–14]. A small subset of patients with
INPH have raised T-tau levels on their initial lumbar samples,
explained possibly by co-existing neurodegenerative disorder
or a more progressive form of INPH [12]. It has been sug-
gested that this subset of patients would be poor surgical can-
didates; however there is a paucity of literature describing
outcomes in this group [12].
Over the last 10 years at this single centre, patients
with probable INPH have had CSF samples analysed for
total protein, T-tau and Aβ1-42 levels to investigate for
co-existing neurodegenerative disease. Here we present
the results of this large CSF sample cohort from INPH
patients, including those with initial raised T-tau on their
lumbar samples. We present the predictive values for lum-
bar and ventricular CSF T-tau and Aβ1-42 values for
shunt responsiveness.
Materials and method
Study design
Single-centre retrospective analysis of probable INPH patients
with CSF samples collected during August 2006 to January
2016. This study was reported in accordance with the STARD
guidelines [5]. Clinical outcome (referenced standard), CSF
samples analysis for T-tau and Aβ1-42 (index test) and radio-
logical assessments were performed and recorded prospec-
tively. The analysis of the data was performed retrospectively.
Inclusion
Eligible patients required a diagnosis of probable INPH from a
single centre. Only those with samples taken prior to VP shunt
insertion (initial diagnostic LP or LD) or during insertion if a
VP shunt were included into the predictive analysis. Formal
consent for cerebrospinal fluid (CSF) sample analysis and use
of results for research (including publication) was obtained.
Exclusion
Exclusion criteria included loss to follow-up or death before
follow-up. Those without prior lumbar drainage or lumbar
puncture, or a poor response, were not fulfilling the interna-
tional criteria for a diagnosis of probable INPH and therefore
also not included in the ventricular predictive analysis (Fig. 1)
[18]. These two groups were acknowledged in the demo-
graphic data and in the additional analysis.
Diagnostic criteria
Three forms of evidence, based upon the international criteria
for the diagnosis of probable INPH, were used to aid selection
of patients for VP shunt insertion [18]: (1) patients over
40 years of age with a clinical insidious history of the typical
triad of cognitive decline, mobility impairment and urinary
incontinence, (2) characteristic brain imaging (MR images or
CT) showing an un-obstructive ventriculomegaly and (3) pos-
itive clinical response in either mobility or cognition or a re-
duction in episodes of urinary incontinence after extended
lumbar drainage (ELD) or lumbar puncture (LP). Patients
were deemed to have a diagnosis of co-existing neurodegen-
erative disease if they had objective evidence (clinical, radio-
logical and biochemical) and formal diagnosis made indepen-
dently by a consultant neurologist.
Index test: CSF analysis
CSF was sampled for T-tau and Aβ1-42 during any of the
following interventions: LP, ELD or infusion study, VP shunt,
VP shunt revision or reservoir tap test. Samples taken during
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the ELD protocol were taken at the time of drain or catheter
insertion and not after a period of extended drainage. CSF
samples were collected under sterile conditions into 10-ml
Sartstedt polypropylene tubes. CSF sample collection and
storage methods were all in accordance with the consensus
guidelines for CSF biobanking [21]. Samples were sent for
biochemical and enzyme-linked immunosorbent (ELISA)
analysis to measure concentrations of T-tau (INNOTEST
hTAU ELISA, Fujirebio, Ghent), Aβ-42 [INNOTEST β-
amyloid (1–42), Fujirebio, Ghent] and total protein. A techni-
cian, blinded to the clinical results, prospectively recorded
levels of T-tau and Aβ-42. Longitudinal stability in the mea-
surements was ascertained using an elaborate programme of
internal quality control (QC) samples. The laboratory also
takes part in the Alzheimer’s Association external QC pro-
gramme for CSF biomarkers [6]. Intra- and inter-assay coef-
ficients of variation were 12 and 15% for Aβ1-42, respective-
ly, and 3 and 12%, respectively, for T-tau.
Reference standard: clinical outcome
The clinical outcome groups ‘shunt responsive’ or ‘shunt
unresponsive’ provided the reference standard. Outcome
measures were recorded prospectively and analysed retro-
spectively. Three main outcome objective measures were
analysed: (1) Wechsler Adult Intelligence Scale R (WAIS-
R) neuropsychology report (any improvement observed in
verbal IQ, performance IQ or full scale IQ), (2) timed 10-
m walking test (a minimum of 5% improvement in either
time in seconds or number of steps, or both) and (3) blad-
der control (with improvement being the reduction of ep-
isodes of incontinence per day of 1 or less). Assessments
were done by personnel blinded to the index test result.
For outcome analysis, an ‘improvement’ reflected better
outcome in at least one of the three objective measures, in
addition to reported subjective improvement. A deteriora-
tion in any one of these clinical elements resulted in an
Fig. 1 Flow chart of patient
participants. A total of 87
samples, 71 primary ventricular
and 30 primary lumbar (from 65
patients), were included in the
final predictive value analysis.
Secondary samples (43) and
samples from those with poor or
no ELD/LP were included in the
longitudinal analysis of markers
in CSF drainage and in analysis of
rostro-caudal gradients
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overall outcome of ‘no improvement’. All outcome data
were processed on an anonymous database.
Statistical analysis
Sample means and variation: Samples were grouped into pri-
mary CSF collection (i.e. taken prior to the shunt) and second-
ary (i.e. taken to test the functioning of a shunt or as part of a
revision surgery). Mean levels of T-tau and Aβ-42 were re-
ported with standard deviation. Mean levels were compared
between the various sample collection groups (lumbar vs. pri-
mary ventricular vs. secondary ventricular) using analysis of
variance (ANOVA with a Geisser-Greenhouse’s epsilon cor-
rection). Linear regression analysis was performed to deter-
mine the effect of age on T-tau and Aβ-42 levels.
Exploratory analysis: ROC analysis was used to assess
predictive values for overall shunt responsiveness, mobility,
cognition and urinary continence. Area under the ROC
(AUROC) levels were implied to suggest the predictive valve
of a test as the following: 0.80–0.90 = good, 0.70–0.79 = fair,
0.60–0.69 = poor and 0.50–0.59 = no differentiation. Optimal
cut-off values derived from ROC analysis are presented with
95% confidence intervals.
Pre-specified analysis: Contingency tables presenting the
negative and positive predictive values (NPV and PPV), sen-
sitivity and specificity of T-tau and AB1-42 were then deter-
mined using the following published cut-off values for INPH:
T-tau protein levels < 425.7 ng/l ± 244.3, Aβ-42 > 500 ng/l
and a ratio of T-tau to Aβ-42 of <1 [17]. This was repeated
using the ROC calculated optimal cut-off values. All values
were expressed as percentages with ‘exact’ Clopper-Pearson
confidence intervals with Fisher’s exact test results. All statis-
tical tests were performed in GraphPad Prism v6.0.
Results
Study profile
August 2006 to January 2016, a total of 144 CSF samples
were analysed from 79 probable INPH patients:
31 females:48 males (31 F:48 M) of mean age 75.3 (R 55–
94). Mean follow-up was 959 ± 657 days (mean ± SD).
Figure 1 outlines the study profile.
Demographics
The frequency of clinical characteristics in both the shunt
responsive and non-responsive groups is demonstrated in
Table 1. There was no significant difference in the frequency
of co-morbidities (Table 1).
T-tau levels and Aβ-42 ratio levels correlated with increas-
ing age on linear regression analysis. When the results from
the three patients under the age of 60 were excluded from the
analysis, this correlation was no longer significant (p = 0.09,
R2 = 0.04). The three patients under the age of 60 were in-
cluded in the full analysis.
The mean duration of the symptoms of INPH prior to CSF
analysis was 290.5 ± 491.1 days. The mean time to VP shunt
insertion after LP or LD was 226.9 ± 218.7 days. The mean
Table 1 Clinical characteristics
Overall (n = 65) Shunt responsive
(n = 46) 70%
Non-responsive
(n = 19) 30%
p-value
Mean age (years) 75.3 74.9 75.7 1.00
Alzheimer’s disease 5 (6.33%) 3 (6.62%) 2 (15.8%) 1.00
Parkinson’s disease 5 (7.69%) 4 (8.70%) 1 (5.26%) 1.00
Lewy-body dementia 3 (4.62%) 3 (6.52%) 0 (0.00%) 0.54
Frontal-temporal lobe dementia 1 (1.54%) 1 (2.18%) 0 (0.00%) 1.00
Cerebral infarct or haemorrhage 3 (4.62%) 2 (4.35%) 1 (5.26%) 0.62
Other neurological disease a 4 (6.15%) 2 (4.35%) 2 (15.8%) 0.57
Depression 4 (6.15%) 1 (2.18%) 3 (10.6%) 0.07
Coronary/peripheral vascular disease 40 (61.5%) 29 (63.0%) 11 (57.9%) 0.78
Urinary dysfunctionb 10 (15.4%) 8 (17.4%) 2 (15.8%) 0.71
Musculoskeletal diseasec 13 (20.0%) 10 (21.7%) 3 (10.6%) 0.74
Visual disturbance 1 (1.54%) 2 (4.35%) 1 (5.26%) 1.00
a Included: Progressive supranuclar palsy, multiple sclerosis, motor neurone diseases, multiple system atrophy, myasthenia gravis, amyloidosis, periph-
eral neuropathy, spinocerebellar ataxia, benign paroxysmal positional vertigo, Meniere’s disease, essential tremor and other movement disorders
b Including benign prostatic hypertophy
c Including spinal stenosis
2296 Acta Neurochir (2017) 159:2293–2300
time from VP shunt insertion to reservoir tap test was 739.1 ±
325.5 days.
Neurodegenerative disease
Fourteen patients had a post-operative neurodegenerative di-
agnosis (5 Parkinson’s disease, 5 AD, 3 Lewy-body dementia
and 1 frontal-temporal lobe dementia). The presence of a neu-
rodegenerative diagnosis did not significantly affect outcome
(Table 1). Eleven of 14 patients with a neurodegenerative
diagnosis were still shunt responsive.
Mean levels per site
Mean levels of Aβ1-42 and T-tau per sampling method are
presented for INPH and INPH patients with a co-existing neu-
rodegenerative disease (Table 2). The range of T-tau levels in
primary lumbar CSF varied from 68 to 872 ng/l and from 56 to
2085 ng/l in primary ventricular samples. Aβ1-42 levels
ranged from 111 to 911 ng/l in lumbar samples and 100–
1231 in primary ventricular samples. Mean CSF levels of T-
tau in samples taken during LP or LD were significantly lower
than in the samples seen during VP shunt insertion (p = 0.001).
ROC analysis of T-tau and Aβ-42 and shunt response
AUROC for lumbar CSF levels of T-tau was 0.6, for T-tau/
Aβ-42 0.62, respectively, with Aβ-42 being 0.5. The
AUROC for ventricular CSF levels of T-tau, Aβ-42 and T-
tau/Aβ-42 were 0.70, 0.51 and 0.64, respectively.
The analysis of lumbar and ventricular samples was repeat-
ed for the individual components of outcome: mobility, cog-
nition and urinary continence. T-tau and Aβ-42 levels in both
lumbar (Fig. 2a–c) and ventricular samples (Fig. 2d–f) were
poor predictors of outcome, with the exception of lumbar T-
tau for predicting improvement in mobility. Lumbar CSF T-
tau had an AUROC of 0.84 (p = 0.04), making it a potentially
good predictor of mobility outcome (Fig. 2). Although graph-
ically ventricular T-tau and urinary continence outcome ap-
pears promising, with an AUROC of 0.78, the result is not
significant (p = 0.19).
Predictive values for T-tau and Aβ-42 and shunt response
Optimal predictive cut-off values derived from ROC analysis
for T-tau in lumbar samples were < 196.5 ng/l and < 525 ng/l
in ventricular samples. The predictive values of degenerative
markers in lumbar CSF and ventricular CSF are presented in
Tables 3 and 4, respectively.
Complications
One patient developed an infection as a result of a clinically
indicated reservoir tap test. This patient was treated with in-
travenous antibiotics. There were no mortalities associated
with CSF sampling.
Discussion
Mean T-tau and Aβ1-42 levels in the CSF of patients
with probable INPH
We have performed a singe-centre analysis of T-tau and Aβ1-
42 levels in the CSF of patients with probable INPH. This is
one of the most comprehensive presentations of CSF samples
from INPH patients to date, thus providing further reference
values to the current literature [2]. The mean lumbar CSF
levels of T-tau in INPH were found to be lower than levels
expected in normal controls, a finding observed in several
studies [8, 11, 13]. We also confirmed previous findings of a
rostro-caudal gradient with significantly lower levels of T-tau
in lumbar CSF than in ventricular CSF [19]. Regardless of the
sampling method, the range for both markers was wide,
Table 2 Mean levels of T-tau and Aβ-42 in 144 CSF samples taken from various sites (ng/l)
Primary (before VP shunt insertion) (n = 101) Secondary (after VP shunt insertion) (n = 43)
Lumbar (n = 30) Ventricular (n = 71) Lumbar (n = 2) Ventricular (n = 41)
Sample ± SD LP (n = 7) LD (n = 23) EVD (n = 1) VP (n = 70) Infusion (n = 2) Tap test (n = 17) VP revision (n = 24)
T-tau overall 303 ± 245 275 ± 205 903 600 ± 429 541 ± 110 373 ± 290 620 ± 664
INPH + NDa 462 ± 446 282 ± 170 601 ± 455 – 655 ± 755 319 ± 343
INPHb 223 ± 138 228 ± 159 – 522 ± 110 – 372 ± 289 538 ± 261
Aβ-42 overall 675 ± 524 534 ± 206 198 460 ± 280 532 ± 354 571 ± 300 576 ± 286
INPH + NDa 909 ± 849 710 ± 137 – 597 ± 455 – 425 ± 170 413 ± 216
INPHb 675 ± 524 525 ± 203 – 472 ± 532 – 464 ± 295 565 ± 285
a INPH + ND = Only patients with a diagnosis of INPH + a post-operative diagnosis of neurodegenerative diagnosis
b INPH = excluding results from patients with a post-operative or delayed diagnosis of neurodegenerative diagnosis
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particularly T-tau, and therefore the authors recommend cau-
tion when interpreting their levels in the context of prognosis
for individual patients.
The predictive value of Aβ1-42 and T-tau for shunt
response in INPH
Ventricular Aβ1-42 and T-tau have previously been demon-
strated to be potentially clinically useful biomarkers for prog-
nosis in INPH [20]. The AUROC values for ventricular T-tau
(general post-shunt outcome) and lumbar T-tau (mobility out-
come) were 0.70 and 0.80. This result concurs with the
findings by Kang et al. in which low levels of tau correlated
with gait dysfunction [13]. Kang et al. also found that lower
levels of Aβ1-42 correlated with poor cognitive outcome in
INPH; however our results did not mirror this, possibly due to
low numbers within this sub-group [13].
The observation that lumbar samples have a better predic-
tive value than ventricular samples is interesting. One possible
explanation may relate to the hypothesis that tau has reduced
clearance in INPH, hence lower levels in CSF [8]. Therefore
lumbar CSF T-tau levels may be even lower, owing to the
greater distance from metabolically active tissue, thus exag-
gerating the predictive value.
Fig. 2 ROC curve demonstrating ability CSF levels of T-tau, Aβ1-42
levels and the ratio T-tau/Aβ1-42 to predict improvement in the triad of
symptoms a–c lumbar primary CSF a mobility (n = 21), b cognition
(n = 13) and c continence (n = 5). d–f Ventricular primary CSF d
mobility (n = 36), e cognition (n = 17) and f continence (n = 9)
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Patients with raised T-tau CSF can still benefit from shunt
insertion
Current literature emphasises differentiating INPH and AD;
however there are patients with NPH and neurodegenerative
disease co-existing [8, 12, 14]. Patients with clinical signs of
INPH may not be referred for neurosurgical assessment, if co-
existing neurodegenerative disease is present, as it is assumed to
render surgical intervention ineffective [12]. Our results show
that assumption is not necessarily correct. We found that the
majority of those who had neurodegenerative disease coexisting
with INPHwere still shunt responsive, despite this group having,
on average, raised T-tau on lumbar CSF samples. We conclude
raised levels of T-tau and being shunt-responsive are not mutu-
ally exclusive, and patients with raised T-tau ought not to be
excluded from having a VP shunt on this criterion alone.
Limitations
To control for the heterogeneity of our data, we analyse some of
the samples in subgroups. As a result, the sub-group analysis of
lumbar CSF samples (reviewing gait, cognition and
continence) had reduced statistical power. The authors of this
article are currently studying whether the individual CSF bio-
marker levels predict actual improvements (i.e. will 10% lower
T-tau reflect a 20% improvement in walking speed). To get
more meaningful results, greater numbers are required and
therefore this is an ongoing element of this research.
Future research
Further research into discovery of biomarkers, or even a panel
of markers, in INPH remains warranted. Since this study com-
menced there have been advances in biomarker discovery and
there are now numerous potential biomarkers to be studied in
INPH [2]. One example of an effective combination of
markers includes Aβ1-42, neurofilament light protein (NF-
L) and phosphorylated-tau (p-Tau), a promising panel to dis-
tinguish iNPH [2]. Furthermore, there are very few studies
measuring levels of marker levels over time with CSF drain-
age. This group is currently studying how shunt insertion
changes the CSF biomarker profile in an individual. Such
research may further elucidate the pathophysiology of INPH
as well as assist in identifying shunt malfunctions.
Table 4 Contingency table for
primary ventricular CSF (VP
shunt insertion) (n = 57)
T-Tau
[ROC - cut-off]
T-Tau low
<425 [<525] ng/l
Normal Total
Shunt responsive 26 [30] 12 [8] 38 Sensitivity 81% [81%]
Non-responsive 6 [7] 13 [12] 19 Specificity 52% [60%]
Total 32 [37] 25 [20]
PPV 68% [78%] NPV 68% [63%]
Fisher’s exact test p = 0.02 [p = 0.02, 95% CI 59–86% sensitivity and 95% CI 34–79% specificity]
Aβ-42 Aβ-42 Low Normal Total
Shunt responsive 23 15 38 Sensitivity 64%
Non-responsive 13 6 19 Specificity 28%
Total 36 21
PPV 61% NPV 32%
Fisher’s exact test p = 0.77
Table 3 Contingency table
primary lumbar CSF (LD or LP)
(n = 30)
T-Tau
[ROC - cut-off]
T-Tau low
<425 [196.5] ng/l
Normal Total
Shunt responsive 17 [13] 6 [10] 23 Sensitivity 81% [86%]
Non-responsive 4 [2] 3 [5] 7 Specificity 33% [33%]
Total 21 [15] 9 [15]
PPV 74% [56%] NPV 43% [43%]
Fisher’s exact test p = 0.64 [p = 0.38, 95% CI 34–77% sensitivity and 95% CI 29–96% specificity]
Aβ-42 Aβ-42 Low Normal Total
Shunt responsive 11 12 23 Sensitivity 79%
Non-responsive 3 4 7 Specificity 25%
Total 14 16
PPV 48% NPV 57%
Fisher’s exact test p = 1.00
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Conclusion
Raised levels of T-tau and being shunt-responsive are not mutu-
ally exclusive. This is highly relevant, since many units would
have presumed such patients (i.e. those with Alzheimer’s disease
and INPH) to be poor surgical candidates. In general, INPH
exhibits low levels of CSF T-tau, and levels can be good predic-
tors of outcome. However, we discourage diagnosis and out-
come prediction based on T-tau levels alone, as its CSF levels
are highly variable between individuals. It is likely that a com-
bined panel of markers, including T-tau, will be a more specific
method for aiding selection of patients for VP shunt insertion.
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